Cite
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
MLA
Gentile, Massimo, et al. “Elotuzumab, Lenalidomide, and Dexamethasone as Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 300 Cases Outside of Controlled Clinical Trials.” Haematologica, vol. 106, no. 1, Jan. 2021, pp. 291–94. EBSCOhost, https://doi.org/10.3324/haematol.2019.241513.
APA
Gentile, M., Specchia, G., Derudas, D., Galli, M., Botta, C., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Attingenti, E., Lombardo, A., Brunori, M., Rossi, E., Antonioli, E., Ria, R., Zambello, R., Di Renzo, N., Mele, G., … Morabito, F. (2021). Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. Haematologica, 106(1), 291–294. https://doi.org/10.3324/haematol.2019.241513
Chicago
Gentile, Massimo, Giorgina Specchia, Daniele Derudas, Monica Galli, Cirino Botta, Stefano Rocco, Concetta Conticello, et al. 2021. “Elotuzumab, Lenalidomide, and Dexamethasone as Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 300 Cases Outside of Controlled Clinical Trials.” Haematologica 106 (1): 291–94. doi:10.3324/haematol.2019.241513.